JP2015529236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015529236A5 JP2015529236A5 JP2015532465A JP2015532465A JP2015529236A5 JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5 JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015532465 A JP2015532465 A JP 2015532465A JP 2015529236 A5 JP2015529236 A5 JP 2015529236A5
- Authority
- JP
- Japan
- Prior art keywords
- immunoglobulin
- fragment
- region
- protein
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims 51
- 102000018358 immunoglobulin Human genes 0.000 claims 51
- 239000012634 fragment Substances 0.000 claims 42
- 102000004169 proteins and genes Human genes 0.000 claims 20
- 108090000623 proteins and genes Proteins 0.000 claims 20
- 230000004048 modification Effects 0.000 claims 18
- 238000012986 modification Methods 0.000 claims 18
- 238000006467 substitution reaction Methods 0.000 claims 16
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 claims 13
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 claims 13
- 125000003275 alpha amino acid group Chemical group 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 239000000833 heterodimer Substances 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 11
- 229940072221 immunoglobulins Drugs 0.000 claims 10
- 101710120037 Toxin CcdB Proteins 0.000 claims 9
- 239000003153 chemical reaction reagent Substances 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 101100504121 Mus musculus Ighg gene Proteins 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 3
- 101001055315 Homo sapiens Immunoglobulin heavy constant alpha 1 Proteins 0.000 claims 2
- 101000961156 Homo sapiens Immunoglobulin heavy constant gamma 1 Proteins 0.000 claims 2
- 101000961146 Homo sapiens Immunoglobulin heavy constant gamma 2 Proteins 0.000 claims 2
- 101000961149 Homo sapiens Immunoglobulin heavy constant gamma 4 Proteins 0.000 claims 2
- 102100026217 Immunoglobulin heavy constant alpha 1 Human genes 0.000 claims 2
- 102100039345 Immunoglobulin heavy constant gamma 1 Human genes 0.000 claims 2
- 102100039346 Immunoglobulin heavy constant gamma 2 Human genes 0.000 claims 2
- 102100039347 Immunoglobulin heavy constant gamma 4 Human genes 0.000 claims 2
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 101000961145 Homo sapiens Immunoglobulin heavy constant gamma 3 Proteins 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102100039348 Immunoglobulin heavy constant gamma 3 Human genes 0.000 claims 1
- 238000001042 affinity chromatography Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705278P | 2012-09-25 | 2012-09-25 | |
| US61/705,278 | 2012-09-25 | ||
| PCT/EP2013/069989 WO2014049003A1 (en) | 2012-09-25 | 2013-09-25 | Purification of hetero-dimeric immunoglobulins |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Division JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Division JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015529236A JP2015529236A (ja) | 2015-10-05 |
| JP2015529236A5 true JP2015529236A5 (https=) | 2016-11-10 |
Family
ID=49237223
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015532465A Pending JP2015529236A (ja) | 2012-09-25 | 2013-09-25 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018020450A Pending JP2018104444A (ja) | 2012-09-25 | 2018-02-07 | ヘテロ二量体免疫グロブリンの精製 |
| JP2018224809A Expired - Fee Related JP6856610B2 (ja) | 2012-09-25 | 2018-11-30 | ヘテロ二量体免疫グロブリンの精製 |
| JP2020036853A Ceased JP2020105203A (ja) | 2012-09-25 | 2020-03-04 | ヘテロ二量体免疫グロブリンの精製 |
| JP2022092045A Pending JP2022116326A (ja) | 2012-09-25 | 2022-06-07 | ヘテロ二量体免疫グロブリンの精製 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150239991A1 (https=) |
| EP (2) | EP2900696A1 (https=) |
| JP (5) | JP2015529236A (https=) |
| KR (1) | KR20150076172A (https=) |
| CN (1) | CN104968685A (https=) |
| AU (2) | AU2013322710A1 (https=) |
| CA (2) | CA2886036A1 (https=) |
| HK (1) | HK1215950A1 (https=) |
| IL (2) | IL237872B (https=) |
| IN (1) | IN2015MN00139A (https=) |
| WO (1) | WO2014049003A1 (https=) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| KR20120108967A (ko) | 2009-09-16 | 2012-10-05 | 제넨테크, 인크. | 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도 |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価抗原結合タンパク質 |
| WO2012116926A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Antigen binding proteins |
| CA2886036A1 (en) * | 2012-09-25 | 2014-04-03 | Ichnos Sciences SA | Purification of hetero-dimeric immunoglobulins |
| KR20210094669A (ko) | 2013-04-29 | 2021-07-29 | 에프. 호프만-라 로슈 아게 | 인간 fcrn-결합 변형된 항체 및 사용 방법 |
| US11261262B2 (en) * | 2013-09-03 | 2022-03-01 | Novimmune Sa | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| KR20160044060A (ko) | 2013-10-11 | 2016-04-22 | 에프. 호프만-라 로슈 아게 | 다중특이적 도메인 교환된 통상의 가변 경쇄 항체 |
| CN110627907B (zh) * | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
| RU2698969C2 (ru) | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с улучшенной способностью связываться с белком а |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| WO2016016299A1 (en) * | 2014-07-29 | 2016-02-04 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| BR112017011166A2 (pt) | 2014-11-26 | 2018-02-27 | Xencor, Inc. | anticorpos heterodiméricos que se ligam a cd3 e cd38 |
| CN107001482B (zh) | 2014-12-03 | 2021-06-15 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| ES2973885T3 (es) | 2015-07-09 | 2024-06-24 | Genmab As | Anticuerpos biespecíficos y multiespecíficos y método para aislarlos |
| HRP20211528T1 (hr) | 2015-10-25 | 2021-12-24 | Sanofi | Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| HRP20231188T1 (hr) | 2016-04-13 | 2024-02-02 | Sanofi | Trispecifični i/ili trovalentni vezujući proteini |
| IL262241B2 (en) * | 2016-04-13 | 2024-05-01 | Sanofi Sa | Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases |
| AU2017259869A1 (en) * | 2016-05-02 | 2018-09-27 | F. Hoffmann-La Roche Ag | The contorsbody - a single chain target binder |
| CN109790215B (zh) | 2016-09-29 | 2023-06-30 | 北京韩美药品有限公司 | 异源二聚体免疫球蛋白构建体和其制备方法 |
| JP7031810B2 (ja) | 2016-11-18 | 2022-03-08 | ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造形態のヘテロダイマー系二重特異性抗体及びその製造方法 |
| AU2018250641B2 (en) | 2017-04-11 | 2025-03-13 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs having constrained CD3 binding and methods of using the same |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN111902720B (zh) | 2018-03-21 | 2025-02-07 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| BR112020020604A2 (pt) | 2018-04-11 | 2021-01-12 | Inhibrx, Inc. | Construções de polipeptídeo multiespecífico tendo ligação restrita de cd3 e métodos e usos relacionados |
| FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
| CN112513074A (zh) * | 2018-06-22 | 2021-03-16 | 健玛保 | 生产两种或更多种不同抗体的受控混合物的方法 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| WO2020077257A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Pd-1 single domain antibodies and therapeutic compositions thereof |
| CA3115082A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | B7h3 single domain antibodies and therapeutic compositions thereof |
| WO2020076992A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | 5t4 single domain antibodies and therapeutic compositions thereof |
| EP3864045A2 (en) | 2018-10-11 | 2021-08-18 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| IL284317B2 (en) | 2018-12-24 | 2025-10-01 | Sanofi Sa | Multispecific binding pseudo-fab proteins |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| WO2021130717A1 (ko) * | 2019-12-26 | 2021-07-01 | 에이비엘바이오 주식회사 | 단백질 a 친화성 크로마토그래피를 이용한 생리활성 펩티드의 정제 방법 |
| CN115380047A (zh) | 2020-01-29 | 2022-11-22 | 印希比股份有限公司 | Cd28单结构域抗体及其多价和多特异性构建体 |
| CN116096758A (zh) * | 2020-05-01 | 2023-05-09 | 诺华股份有限公司 | 工程化免疫球蛋白 |
| IL301956A (en) | 2020-10-07 | 2023-06-01 | Dren Bio Inc | Antibodies against dectin-1 and methods of using them |
| US20240279341A1 (en) | 2021-06-16 | 2024-08-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| JP2023092810A (ja) * | 2021-12-22 | 2023-07-04 | 国立大学法人東京農工大学 | 変異抗体、変異抗体の製造方法 |
| WO2024026472A2 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| KR20250035053A (ko) | 2022-06-07 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도 |
| WO2024026471A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| US20260070987A1 (en) * | 2022-09-02 | 2026-03-12 | Zoetis Services Llc | Equine antibody mutants |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025087386A1 (zh) * | 2023-10-25 | 2025-05-01 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
| WO2025264572A1 (en) | 2024-06-17 | 2025-12-26 | Alector Llc | Transferrin receptor antigen-binding domains and uses therefor |
| WO2026013159A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
| WO2026013158A1 (en) | 2024-07-10 | 2026-01-15 | Cytospire Therapeutics Limited | Antibodies binding to constant domains of gamma delta t-cell receptors |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| DE69132709T2 (de) | 1990-06-29 | 2002-06-20 | Large Scale Biology Corp., Vacaville | Melaninproduktion durch transformierte mikroorganismen |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| ATE218143T1 (de) | 1996-09-03 | 2002-06-15 | Gsf Forschungszentrum Umwelt | Verwendung bi-und trispezifischer antikörper zur induktion einer tumorimmunität |
| US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| TWI372763B (en) * | 2005-06-17 | 2012-09-21 | Wyeth Llc | Methods of purifying anti a beta antibodies |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| SG178789A1 (en) | 2007-02-16 | 2012-03-29 | Merrimack Pharmaceuticals Inc | Antibodies against erbb3 and uses thereof |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| JP6126782B2 (ja) * | 2008-10-01 | 2017-05-10 | アムゲン リサーチ （ミュンヘン） ゲーエムベーハー | 異種間特異的ｐｓｍａ×ｃｄ３二重特異性単鎖抗体 |
| CA2746330C (en) * | 2008-12-23 | 2017-08-29 | Genentech, Inc. | Immunoglobulin variants with altered binding to protein a |
| EP2398829A2 (en) | 2009-02-23 | 2011-12-28 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| CN104447995A (zh) | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| KR101856792B1 (ko) * | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| DK2560993T3 (da) * | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| US9683052B2 (en) | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
| US10344050B2 (en) * | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| AU2012372484A1 (en) | 2012-03-06 | 2014-08-21 | Foss Analytical Ab | Method, software and graphical user interface for forming a prediction model for chemometric analysis |
| PT2825559T (pt) | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
| CA2886036A1 (en) * | 2012-09-25 | 2014-04-03 | Ichnos Sciences SA | Purification of hetero-dimeric immunoglobulins |
| CN110627907B (zh) * | 2013-11-04 | 2024-03-29 | 艾科诺斯科技股份有限公司 | 重靶向t细胞的异源二聚免疫球蛋白的产生 |
-
2013
- 2013-09-25 CA CA2886036A patent/CA2886036A1/en not_active Abandoned
- 2013-09-25 CA CA3061557A patent/CA3061557A1/en active Pending
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/en not_active Ceased
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Ceased
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/en not_active Withdrawn
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/en not_active Ceased
- 2013-09-25 HK HK16103843.5A patent/HK1215950A1/zh unknown
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja not_active Ceased
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015529236A5 (https=) | ||
| JP6856610B2 (ja) | ヘテロ二量体免疫グロブリンの精製 | |
| KR102440737B1 (ko) | 이중특이적 항체에 대한 정제 플랫폼 | |
| JP6273219B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP5816170B2 (ja) | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 | |
| JP2020506898A5 (https=) | ||
| JP2014158485A5 (https=) | ||
| JP2011505810A5 (https=) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2013520984A5 (https=) | ||
| JP2021530244A5 (https=) | ||
| JP2021517459A5 (https=) | ||
| JP2016518333A5 (https=) | ||
| JP2025146842A (ja) | 抗ｇａｌ９免疫阻害性結合分子 | |
| US12545702B2 (en) | Methods for removing undesired components during multistage chromatographic processes | |
| WO2023137062A1 (en) | Methods for improving resolution of heterodimeric proteins from impurities using affinity chromatography | |
| EA049572B1 (ru) | Способы удаления нежелательных компонентов в многостадийных хроматографических процессах | |
| NZ737843B2 (en) | Tau-binding antibodies | |
| TH143301A (th) | นิวทรอลไลซ์ซิ่ง แอนติ-CCL-20 แอนติบอดี้ (NEUtralizing Anti-CCL-20 Antibodies) | |
| NZ774327B2 (en) | Therapeutic antibodies and their uses | |
| NZ724772B2 (en) | ANTIBODIES AGAINST HPA-1a |